SPARC and pancreatic adenocarcinoma: However, in the phase III Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone, no association was found between stromal, tumor epithelial, or plasma SPARC expression and either survival or ORR in patients with metastatic pancreatic cancer [47].